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poor prognosis metastatic breast cancer-a phase I/II study
DA Cameron" 2, J Craig3, H Gabral 2, L Lee', J MacKay' 2, AC Parker3 and RCF Leonard' on
behalf of the Edinburgh Breast Group (E Anderson, T Anderson, U Chetty, M Dixon,
A Hawkins, W Jack, I Kunkler, R Leonard, L Matheson and W Miller)
'Directorate of Clinical Oncology and 2ICRF Medical Oncology Unit, Western General Hospital, Edinburgh, UK; 3Department of
Haematology, Royal Infirmary, Edinburgh, UK.
Summary Current treatments for metastatic breast cancer are not associated with significant survival benefits
despite response rates of over 50%. High-dose therapy with autologous bone marrow transplantation (ABMT)
has been investigated, particularly in North America, and prolonged survival in up to 25% of women has been
reported, but with a significant treatment-related mortality. However, in patients with haematological
malignancies undergoing autologous transplantation, haematopoietic reconstruction is significantly quicker and
mortality lower than with ABMT, when peripheral blood progenitor cells (PBPCs) are used. In 32 women with
metastatic breast cancer, we investigated the feasibility of PBPC mobilisation with high-dose cyclophosphamide
and granulocyte colony-stimulating factor (G-CSF) after 12 weeks' infusional induction chemotherapy and the
subsequent efficacy of the haematopoietic reconstitution after conditioning with melphalan and either etoposide
or thiotepa. PBPC mobilisation was successful in 28/32 (88%) patients, and there was a rapid post-
transplantation haematopoietic recovery: median time to neutrophils >0.5 x l09 1 -1 was 14 days and to
platelets >20 x 109 1 was 10 days. There was no procedure-related mortality, and the major morbidity was
mucositis (WHO grade 3-4) in 18/32 patients (56%). In a patient group of which the majority had very poor
prognostic features, the median survival from start of induction chemotherapy was 15 months. Thus, PBPC
mobilisation and support of high-dose chemotherapy is feasible after infusional induction chemotherapy for
patients with metastatic breast cancer, although the optimum drug combination has not yet been determined.
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Metastatic breast cancer is usually considered incurable, and
treatment aims to relieve symptoms. The presence of visceral
involvement carries a particularly poor prognosis with a
median survival of less than 6 months (Gregory et al., 1993),
and conventional chemotherapy has little or no impact on
survival beyond 1-2 years. This may, in part, be because the
dose of drug that can be delivered is limited by toxicity; there
is certainly some evidence for a dose response curve within
the range of doses that are conventionally given (Hryniuk
and Bush, 1984), particularly when their mode of action is
alkylation (Frei et al., 1989). Early attempts at circumventing
dose-limitation because of haematological toxicity, by using
autologous bone marrow rescue, were associated with poor
results and significant treatment-related mortality (Tannir et
al., 1984; Vincent et al., 1988); however, more recent series
report a much lower mortality of around 5% (Antman et al.,
1992). The discovery that, following myeloablative che-
motherapy, previously mobilised peripheral blood progenitor
cells were able to reconstitute haematopoiesis more rapidly
than those from bone marrow (Schmitz et al., 1994) offered
the opportunity to reduce some of the toxicity associated
with high-dose chemotherapy.
We therefore investigated the feasibility of performing
myeloablative chemotherapy for younger women whose sites
of metastatic breast cancer carried a particularly poor
prognosis. In view of the data suggesting that this approach
held more promise in chemosensitive breast cancer (Antman
et al., 1992) together with the need to improve the
performance status of some patients presenting with stage
IV disease, we opted for a 12 week induction chemotherapy
regimen to precede the high-dose cycles. The initial high-dose
regimen consisted of melphalan and etoposide, which has a
low toxicity in the management of lymphoma (Jackson et al.,
1994) and which would be anticipated to have activity in
breast cancer. However, although we found this regimen to
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be active, the data on single agent etoposide in breast cancer
suggested that this may not be the most effective drug to
employ, and thus after ten patients the intention was to
conduct a phase I study was melphalan and thiotepa; the
latter drug being chosen because of its efficacy in breast
cancer (Antman, 1992) as well as its superior in vitro activity
after dose escalation (Lazarus et al., 1987).
Patients and methods
Between July 1992 and April 1995, we entered 32 women
(median age 39, range 27-55 years) with metastatic breast
cancer into a phase I/II study of myeloablative chemotherapy
supported by peripheral blood progenitor cells. Patients had to
have histologically confirmed breast cancer, with definite
evidence of relapsed or metastatic disease (see Table I). The
presence of metastases in bone only was insufficient for entry
into this study. Thirty patients had an induction regimen of
infusional chemotherapy (AcF) consisting of weekly adriamy-
cin (20 -30 mg m-2) and continuous 5-fluorouracil (5-fu)
200 mg m-2 day-' delivered using an electronic pump
(CADD, Pharmacia; or Walkmed, Medex) through a Hick-
man line for up to 12 weeks. The responses and toxicities of this
regimen have been separately reported (Gabra et al., 1996) and
will not be discussed further. Patients progressing on this
regimen were switched to ECF (epirubicin 50 mg m2, cisplatin
60 mg m-2, 5-FU 200 mg m-2 day-') (Jones et al., 1994); one
women was given only ECF as induction, and one was referred
after treatment with 3 weekly FEC (5-fluorouracil, epirubicin,
cyclophosphamide). Patients objectively responding to the
induction regimen (and with adequate cardiac function) were
then eligible for this study, which was approved by the Lothian
ethics committee. Informed consent was obtained from each
patient.
Peripheral blood progenitor cells (PBPC) were mobilised
using cyclophosphamide 2.5 g m-2 (n =5) or 4 g m-2 (n = 27)
and 300 jug G-CSF(Amgen) administered from day + 1 until
harvesting was complete (Craig et al., 1993). PBPC harvesting
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was performed on 3 consecutive days using the Baxter
CS3000 plus or Cobe Spectra cell separators commencing
after the total white blood cell count was greater than
I x 1091-'. The product was diluted 1:1 with autologous
plasma containing 20% dimethyl sulphoxide (DMSO),
cryopreserved using a controlled rate freezer and stored in
the vapour phase of liquid nitrogen. Progenitor cells were
assessed using the CFU-GM assay in methyl cellulose, as
previously described (Craig et al., 1992), with a locally
determined safe transplantation threshold of 10 x 104 CFU-
GM kg-' (Craig et al., 1993). Conditioning was commenced
once the CFU-GM assays were available and, if the harvest
was inadequate, a bone marrow harvest was carried out
under general anaesthesia. Initially ten patients were given
etoposide 1600 mg m-2 over 48 h, followed by melphalan
140 mg m-2. Subsequently, 22 patients had thiotepa
500 mg m-2 over 4 days in place of etoposide. Twenty-
four hours after melphalan the cryopreserved PBPC were
rapidly thawed at the bedside in a 37°C water bath and
reinfused via the Hickman line. The patients were then
allowed home, but reattended daily for blood counts.
Prophylactic antimicrobials (ciprofloxacin 500 mg b.d.,
fluconazole 50 mg o.d. and acyclovir 200 mg q.d.s) were
commenced on readmission to hospital when the neutrophil
count fell below 0.5 x 109 cells 1-'. Thereafter, patients were
reverse-barrier nursed until the neutrophil count rose above
0.5 x 109 1-'. Other supportive measures were employed as
necessary, and febrile episodes were initially treated with
gentamicin and ceftazidime. All blood products were
irradiated, and patients who were seronegative for
cylomegalovirus (CMV) received CMV-negative products.
Platelets were administered prophylactically to maintain
platelets > 5 x 109 1-'.
Following high-dose chemotherapy, patients were treated
with adjuvant hormone therapy irrespective of their
oestrogen receptor (ER) status. Those who had previously
Table I Summary of patients' data
received tamoxifen (11/32) were advised to take megestrol
acetate 160 mg daily; the remainder (21/32), tamoxifen 20 mg
daily. One month following recovery of the bone marrow,
patients were restaged to assess their response to the therapy.
Thereafter, follow-up was 3 monthly until relapse, when
patients were treated as was considered appropriate. Isolated
bone metastases were irradiated and, if systemic therapy was
required, chemotherapy was used (routinely CMF, i.e.
cyclophosphamide 600 mg m-2, methotrexate 50 mg m-, 5
fluorouracil 600 mg ml -2).
Statistical analysis
All survival analyses have been done using the Kaplan Meier
method, and statistical comparisons were made using the log-
rank test. These were performed using the 'Sureal' programme
(W Gregory, personal communication) running under MS-
DOS 6.2 (Microsoft). All other statistical calculations were
carried out in Minitab version 5.1.1 (Minitab, State College,
PA, USA), also running under MS-DOS 6.2. The confidence
interval for the mortality was estimated using the binomial
distribution function in Minitab.
Results
Response
Thirty women underwent initial induction with AcF, of
whom four progressed and were therefore treated with ECF,
one received ECF alone and one was referred in complete
response (CR) following four cycles of FEC. There were 8/32(25%) complete responses to the induction chemotherapy, as
assessed before the administration of the high-dose cyclopho-
sphamide, and an overall response rate of 97%. After PBPC
transplantation, this rose to 17/32 complete responses (53%)
with an overall response rate of 100% (see Table II).
Table III High-dose toxicities
At first presentation
Stage I
Stage II
Stage III (including three w
unknown size)
ER positive (>20 fmol mg prote
ER unknown
Before induction therapy
Median age
Prior adjuvant chemotherapy
Prior tamoxifen
Median disease-free interval
Median performance status
Metastatic sites
Liver
Lung
CNS
Locoregional
Visceral (liver/lung/CNS)
aNumbers with percentages in
patients.
3 (9%)a
18 (56%)
8 (25%)
12 (38%)
7 (22%)
39 years (range 27-55)
13 (41%)
11 (35%)
22 months (range 0 -60)
2 (range 0 -4)
median number 2 (range 1 -5)
23 (72%)
9 (28%)
2 (6%)
14 (44%)
25 (78%)
parentheses refer to number of
Haematopoietic
Days to platelets > 20 x 109 1'-
Days to platelets> 50 x 109 1-
Days to neutrophils >0.5 x 109 1-'
Red cell concentrates transfused
Platelet transfusions (in units of 5)
Other
Days of fever
Mucositis WHO grade 3 or 4
Thiotepa/VPl6
Thiotepa/melphalan
Diarrhoea WHO grade 3 or 4
Thiotepa/VPl6
Thiotepa/melphalan
Late toxicities
Shingles
Prolonged low white count
(<2x 1091-')
Table II Response to induction and high-dose therapy
CR PR SD Overall
After induction therapy 8 (25%) 23 (72%) 1 (3%) 31 (97%)
8 [ } / 14 1
After high-dose therapy 17 (53%) 15 (47%) 32 (100%)
CR, complete response; PR, partial response; SD, static disease.
Median
10
13
14
2
1
4
Range
8-17
8-27
8-23
0 - 6 units
0-5
0- 10
4 (40%)
14 (64%)
0 (0%)
4 (18%)
5 (16%)
2 (6%)
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Toxicities
The high-dose cyclophosphamide was well-tolerated. There
was no evidence of cardiac decompensation. Febrile
neutropenia requiring admission occurred in 10/32 (31%)
patients.
Adequate PBPCs were collected from 28/32 (88%)
patients, with a median CFU-GM collected per mobilisation
of 48.5 x 104 kg-' (range 9-191). The four patients with
inadequate PBPC yields had harvested bone marrow
reinfused together with the PBPC. The high-dose regimen
was well-tolerated (see Table III for details). Haematopoietic
reconstitution in those transplanted with only PBPC was
rapid, with a median time to neutrophils >0.5 x 109 1 of 14
days and platelets >20 x 109 1-' of 10 days (see Table III).
(The difference between platelet and neutrophil recovery
times was significant; W= 387.5, P<0.05.) Recovery was
slower in those four patients with inadequate PBPC
recruitment, who therefore also received bone marrow; the
longest time to platelets >20 x l09 1-' was 17 days and to
neutrophils >0.5 x 109 1` was 23 days.
The only major non-haematological toxicity was mucositis,
with 18/32 (56%) experiencing WHO grade 3 or 4 mucositis.
There were no treatment-related deaths. The 5% confidence
interval for this observed mortality of 0% is 0-9%.
Furthermore, no patient required parenteral nutrition or
artificial ventilation. Following therapy, two patients experi-
enced persistent low blood counts (leucocytes <2 x 109 1 -'),
but without any infective problems. Five patients (16%) had
shingles, two had rashes which were not biopsied and two
had self-limiting culture-negative diarrhoea.
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Survival
Progression-free survival from the time of high-dose therapy
is shown in Figure 1. To date, 27 patients have relapsed,
giving a median relapse-free survival of 7.5 months overall
and of 7 months for those with visceral metastases. Six out of
twenty-seven (22%) patients relapsing did so with CNS
involvement. A further two (6%) initially relapsed in bone,
having never before had evidence of bone metastases. All
other patients, including those who had bone marrow
reinfused, relapsed at previous sites of disease. However
four of the five patients remaining disease-free at 1 year are
still in complete remission at 14, 17, 25 and 31 months.
Figure 2 shows the overall survival, with a median value of
12 months from high-dose treatment and 15 months from the
start of induction treatment. Actuarial survival is 35% at 2
years, and 12 patients are still alive with progression-free
survivals of 9, 9+, 14+, 17+, 18, 19, 21, 23, 25, 25+, 27
and 31 + months. There was no difference in progression-free
or overall survival between the patients treated with the two
different high-dose regimens (x2= 1.8 and x2=0.4 respec-
tively). Furthermore, the survival of the small group of seven
women who did not have visceral involvement was not
significantly better than those who did (X2 = 0.67), although
four remain disease-free, including the two longest survivors.
At trial entry, the majority of patients had more than one
site of disease relapse, but there was no difference in outcome
either by the site(s) involved or by the number of different
sites. Furthermore, neither the disease-free interval nor the
original ER status of the tumour nor the administration of
prior adjuvant chemotherapy had any bearing on survival in
this small group of patients. The four patients who had an
autologous bone marrow transplant because of a low PBPC
yield had a poorer survival (x2 = 3.7, P = 0.054) despite two
being in CR after induction and one more converting to CR
after ABMT. Three of these patients had visceral metastases,
and three had also had prior adjuvant CMF, proportions
that were not significantly different from the group as a
whole.
Despite the improved response following the PBPC
transplant, there was no difference in survival depending on
whether or not patients had had a complete response to
either the induction or high-dose regimen (X2 = 0.3 and
x2= 0.1 respectively).
Discussion
5 10 15
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Figure 1 Progression-free survival from
therapy.
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Figure 2 Overall survival from date of hig
20 25 30 We have shown that PBPC transplantation can be safely
performed in patients with visceral metastatic breast cancer.
The toxicity of this approach, even after 12 weeks' infusional
i date of high-dose induction chemotherapy, was acceptable, with the only major
non-haematological toxicity being self-limiting mucositis. The
lack of any treatment-related deaths is consistent with a
mortality of up to 9%, well within the range seen in many of
the reported larger and more recent North American series
using autologous bone marrow (Antman et al., 1992;
Livingston, 1994).
There has, however, been less experience with PBPCs.
They have been used in other series because of overt bone
marrow involvement, with the reported haematopoietic
recovery and patient survival times being similar to those
seen here (Somlo et al., 1994; Myers et al., 1994; Hester and
Wallerstein, 1993; Kritz et al., 1993). In contrast, the more
prolonged recovery for patients receiving ABMT is well
recognised; and although we did not employ G-CSF after
PBPC, this can further hasten neutrophil recovery (van der
Wall et al., 1995), but with no significant effect on antibiotic
usage, febrile days or platelet counts. One study in the high-
risk adjuvant setting reported that the median recovery was
20 25 30 9 days for 18 patients who received G-CSF after return of
the PBPC and 16 days for the ten patients who did not (van
der Wall et al., 1995). Another study with G-CSF given
Jh-dose therapy. after PBPC reinfusion also reported a median recovery time
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of 9-10 days (Somlo et al., 1994), whereas a small study of
12 patients given PBPC alone after high-dose therapy
reported a neutrophil recovery time of 14 days, with
platelet recovery occurring within 12 days (Elias et al.,
1991). Thus, although our observation that the platelets
recovered significantly earlier than the neutrophils has not to
our knowledge been previously noted, this may be a
consequence of the use of G-CSF in some of the other
reports. PBPC transplantation does therefore have the twin
advantages of reducing the period of neutropenia and
thrombocytopenia as well as obviating the need for a
general anaesthetic to harvest the bone marrow.
It is unclear as to which are the best drugs to be
employed in a myeloablative transplant regimen for breast
cancer. Laboratory studies show that melphalan, thiotepa
and cis-platinum demonstrate steep, almost linear dose r-
esponse curves in MCF-7 cells (Frei et al., 1989). Fewer data
are available for etoposide, but poor responses were seen
when it was used as a single high-dose agent in refractory
breast cancer (Antman, 1992). Having established the safety
of melphalan and etoposide with PBPC support in
pretreated metastatic breast cancer, we then administered
thiotepa in place of the etoposide, intending to dose escalate
both the thiotepa and melphalan. However, at the doses
initially used there was a significant increase in mucositis,
with 68% (15/22) patients experiencing grade III or IV
mucositis, most of whom needed intravenous diamorphine
for 3-5 days. This was in contrast to the experience with
etoposide, when only 40% (4/10) had a similar degree of
mucositis. The lack of difference in survival between the two
regimens employed does not necessarily imply that they are
equivalent, as they were employed over different periods and
thus, there may be a selection bias. Indeed, all ten patients
given melphalan and etoposide were classified as having a
complete response following high-dose therapy; but none of
them had stable or progressive disease during the initial AcF
induction therapy, so that they may have represented a
'better' group. Although the in vitro data suggest that prior
treatment with etoposide can have a synergistic enhancement
of the cytotoxicity of alkylators such as BCNU or
cyclophosphamide (Tanaka et al., 1991), one cannot draw
any conclusions from this study about the relative efficacies
of etoposide and thiotepa administered in conjunction with
melphalan.
In the South African randomised trial (Bezwoda et al.,
1995), following all chemotherapy, all patients classified as
responding were given tamoxifen, with 95% of those in the
high-dose arm and only 53% in the conventional arm being
thus treated. Whether this contributed to the observed
survival difference is uncertain, as there were more patients
in the high-dose arm who were known to be ER-negative. In
contrast in this study, all women were given further
'adjuvant' hormone therapy, with megace being given to
those who had relapsed whilst on tamoxifen, as even a
cytostatic effect would provide symptomatic if not survival
benefit for patients in good remission.
The long-term benefit from high-dose chemotherapy
remains uncertain, with many series reporting a 5 year
survival of the order of 25% (Livingston, 1994), not very
different from advanced high grade NHL. The criteria for
offering high-dose chemotherapy in metastatic breast cancer
varies and in this series, as with many others, most of the
patients have a particularly poor prognosis with conven-
tional chemotherapy. Indeed, the presence of liver metastases
predicts for a poor prognosis with both conventional
(Gregory 1993) and high-dose chemotherapy (Dunphy et
al., 1994). Thus, this failure to cure a significant number of
women should not be seen as an indictment of the approach
as, even in this study, the median survival is more than
twice what would be anticipated for patients with liver
metastases. Whether this is acceptable will depend on the
toxicity experienced, but if this degree of extended survival
can be obtained for the majority, then it is essential that the
regimen is well-tolerated. It is not at present clear what the
optimum regimen is for myeloablative therapy in breast
cancer, but the combination of melphalan and thiotepa or
etoposide can be delivered with a lower mortality and
morbidity than one of the most widely used regimens piloted
in North America, i.e. cyclophosphamide/cisplatin/BCNU
(Peters et al., 1988). Another widely used treatment, the so-
called STAMP 5 regimen consisting of carboplatin,
cyclophosphamide and thiotepa (Antman et al., 1992) is
associated with a similarly low mortality but with more
toxicity including 20% transient congestive cardiac failure.
The long-term survival that we report for a smaller group of
women is very similar to that seen with these more toxic
regimens, and there is no apparent loss of response from
using only two drugs, nor from using PBPC harvested after
3 months infusional chemotherapy.
What remains unproved is the strategy. What is the true
benefit of this approach in stage IV breast cancer? A
multicentre randomised trial comparing PBPC-supported
myeloablative therapy with the best conventional non-
ablative therapy is required to determine whether dose
intensification can improve the appalling prognosis for
women with visceral metastatic breast cancer.
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